AUTHOR: LATOYA LANG
The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.
"FDA appreciates the concerns raised by MRA, and agrees with the importance of protecting the confidentiality of personal privacy information, including personally identifiable information, of those persons who participate in consumer surveys or other marketing research. Similarly, FDA understands the importance of protecting confidential commercial information, including trade secret and proprietary information."
MRA had contacted the FDA regarding the agency's sweeping demands for marketing research documents from Phillip Morris USA, Inc. to share our concerns about the need to keep respondents' personal information private and not jeopardize the research process or research trade secrets.
Read the FDA's response.
A recent event hosted by Privacy for America, “The National Privacy Summit,” brought...
Tennessee Sen. Bo Watson III (R-TN-11) and Rep. Johnny Garrett (R-45) introduced the Tennessee Infor...
Illinois Rep. Abdelnasser Rashid (D-21) introduced the Illinois Data Privacy and Prote...
With the insights industry concerned about a wide variety of policy issues, we need to keep on top o...
Privacy legislation and regulation kicked into gear during February at the state and federal level. ...
The leading trade association for the insights industry is urging a key Congressional committee &quo...
0 Comments